NASDAQ$EDIT
Editas Medicine Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Editas Medicine's Q4 2022 results reflected increased research and development expenses and a decrease in collaboration revenue, leading to a higher net loss compared to the same period in 2021.
Editas Medicine reported a net loss of $60.7 million, or $0.88 per share, for the fourth quarter of 2022. Collaboration and other research and development revenues decreased, while research and development expenses increased due to investments in the EDIT-301 program.
- Parallel patient dosing commenced in the EDIT-301 RUBY trial for SCD.
- Clinical update for RUBY trial expected by mid-2023, with plans to dose 20 total patients by year-end.
- First patient dosing in EDIT-301 EDITHAL trial for TDT is on track for Q1 2023, with a clinical update expected by year-end.
- Agreement reached to sell iNK cell franchise and out-license gene editing technologies to Shoreline Biosciences.
Headline financials
Revenue & EPS history
Editas · Revenue · Quarterly
$6.54M
Revenue by segment
Editas · $5.34M total across 1 segment · Q3 2023
- Collaboration & R&D$5.34M+12604.8%100.0%
Forward guidance
Editas Medicine is focused on advancing its EDIT-301 program for SCD and TDT, with key milestones expected in 2023. The company also aims to sharpen its focus, strengthen its technology, and expand business development efforts.
Tailwinds
- On track to provide clinical update for RUBY trial by mid-2023 and dose 20 total patients by year-end.
- On track to dose first patient in EDIT-301 EDITHAL trial for TDT in Q1 2023 and provide clinical update by year-end.
- Entering 2023 with the objective of positioning Editas as a leader in programable in vivo gene editing.
- Bristol Myers Squibb (BMS) recently opted into three additional gene editing programs under the collaboration agreement with Editas Medicine
- Existing cash, cash equivalents and marketable securities will fund operating expenses and capital expenditures into 2025.
Headwinds
- Pausing enrollment in the BRILLIANCE trial and seeking a collaboration partner.
- Net loss attributable to common stockholders was $60.7 million, or $0.88 per share
- Collaboration and other research and development revenues decreased by $6.0 million
- Research and development expenses increased by $14.4 million
- General and administrative expenses increased by $1.5 million
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+4.5%
Avg return
Earnings day
+4.4%
Avg return
5 days after
+2.0%
Avg return
30 days after
71%
29 / 41 earnings
Positive
+29.4%
Q2 2021
Best reaction
-11.8%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.3% | +3.7% | -0.7% | |
| Q4 2025 | +15.5% | +22.0% | +38.0% | |
| Q3 2025 | +1.4% | +5.3% | +5.3% | |
| Q1 2025 | -2.7% | -1.9% | +41.6% | |
| Q4 2024 | +16.5% | -11.4% | -41.5% | |
| Q3 2024 | +7.2% | +7.2% | -31.6% | |
| Q2 2024 | -10.0% | -16.2% | -23.3% | |
| Q1 2024 | -2.1% | +0.5% | -6.7% | |
| Q4 2023 | +13.5% | +12.0% | -16.3% | |
| Q3 2023 | +18.2% | +19.5% | +53.2% | |
| Q2 2023 | +7.6% | -2.5% | +5.0% | |
| Q1 2023 | +10.3% | +14.6% | +10.9% | |
| Q4 2022 | +2.3% | -1.5% | -18.7% | |
| Q3 2022 | -8.5% | -13.4% | -19.6% | |
| Q2 2022 | +16.2% | +16.1% | -10.0% | |
| Q1 2022 | +2.7% | -21.7% | -16.0% | |
| Q4 2021 | +17.3% | +21.4% | +30.2% | |
| Q3 2021 | +8.2% | +1.1% | -14.9% | |
| Q2 2021 | +29.4% | +37.9% | +62.1% | |
| Q1 2021 | -0.9% | -9.7% | -2.9% | |
| Q4 2020 | -11.8% | -8.1% | -18.6% | |
| Q3 2020 | +0.1% | -1.9% | +13.3% | |
| Q2 2020 | +6.8% | +5.2% | -6.2% | |
| Q1 2020 | -1.2% | +1.9% | +6.6% | |
| Q4 2019 | -6.7% | +1.1% | -11.2% | |
| Q3 2019 | +12.8% | +12.1% | +47.8% | |
| Q2 2019 | +2.4% | +3.8% | +1.1% | |
| Q1 2019 | -2.8% | -5.5% | -20.4% | |
| Q4 2018 | +12.8% | +12.8% | +16.7% | |
| Q3 2018 | +10.7% | +4.1% | +4.8% | |
| Q2 2018 | +0.5% | +3.3% | +11.6% | |
| Q1 2018 | +1.0% | +2.4% | +13.2% | |
| Q4 2017 | +9.9% | +14.6% | -14.5% | |
| Q3 2017 | -6.9% | +1.5% | +7.3% | |
| Q2 2017 | +4.6% | +22.8% | +6.5% | |
| Q1 2017 | -5.1% | -7.2% | -17.1% | |
| Q4 2016 | +4.4% | +19.2% | +0.8% | |
| Q3 2016 | +5.1% | +23.6% | +19.4% | |
| Q2 2016 | -9.3% | -15.1% | -27.4% | |
| Q1 2016 | +7.0% | — | — | |
| Q4 2015 | +5.9% | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro